FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3124328448> ?p ?o ?g. }

• W3124328448 endingPage "157" @default.
• W3124328448 startingPage "150" @default.
• W3124328448 abstract "Objectives A phase II trial investigating the therapeutic effect of neoadjuvant programmed cell death 1 (PD-1) inhibitor pembrolizumab (MK-3475, KEYTRUDA®) administered prior to surgery for the treatment of non-small cell lung cancer (NSCLC) has been conducted (NCT03197467). We report the first clinical results of a planned interim safety analysis after 15 patients were enrolled. Material and methods Patients with resectable NSCLC stage II/IIIA were included. Two cycles of pembrolizumab (200 mg intravenously once every 3 weeks) were administered prior to surgery. The primary objectives were to assess the feasibility and safety of neoadjuvant pembrolizumab therapy and to evaluate antitumor activity. We analyzed the clinical parameters as well as pathological and radiological tumor response data. Results The NSCLC histology was adenocarcinoma for 13 patients and squamous cell carcinoma for 2 patients. All patients but two underwent 2 cycles of pembrolizumab prior to surgery. Four patients (27 %) presented a major pathologic response. Significant tumor target response in positron emission tomography computed tomography (PET-CT) was detected in all 4 pathologic responders. Nevertheless, the PET findings mismatched the tumor load in some patients. A PD-L1 expression ≥10 % in the pretreatment biopsy was associated with at least major pathologic response. Five patients (33 %) presented grade 2–3 treatment related adverse events (TRAE), the overall postoperative morbidity was 7 % and 30-day mortality was 0 %. Conclusion Neoadjuvant pembrolizumab is a feasible therapy in surgical lung cancer patients. It was associated with tolerable toxicity and did not compromise tumor resection." @default.
• W3124328448 created "2021-02-01" @default.
• W3124328448 creator A5004352238 @default.
• W3124328448 creator A5010070565 @default.
• W3124328448 creator A5010632119 @default.
• W3124328448 creator A5013804417 @default.
• W3124328448 creator A5024703489 @default.
• W3124328448 creator A5025974644 @default.
• W3124328448 creator A5046577049 @default.
• W3124328448 creator A5053291675 @default.
• W3124328448 creator A5055278162 @default.
• W3124328448 creator A5058552522 @default.
• W3124328448 creator A5061019810 @default.
• W3124328448 creator A5064807273 @default.
• W3124328448 creator A5072714653 @default.
• W3124328448 creator A5076234765 @default.
• W3124328448 creator A5078217749 @default.
• W3124328448 creator A5085505239 @default.
• W3124328448 date "2021-03-01" @default.
• W3124328448 modified "2023-10-18" @default.
• W3124328448 title "Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience" @default.
• W3124328448 cites W2010263122 @default.
• W3124328448 cites W2019607817 @default.
• W3124328448 cites W2042032801 @default.
• W3124328448 cites W2104543228 @default.
• W3124328448 cites W2108549165 @default.
• W3124328448 cites W2109117547 @default.
• W3124328448 cites W2134291074 @default.
• W3124328448 cites W2153169173 @default.
• W3124328448 cites W2160708645 @default.
• W3124328448 cites W2177405394 @default.
• W3124328448 cites W2181211402 @default.
• W3124328448 cites W2198093519 @default.
• W3124328448 cites W2235547202 @default.
• W3124328448 cites W2251438188 @default.
• W3124328448 cites W2556154467 @default.
• W3124328448 cites W2613745448 @default.
• W3124328448 cites W2619866304 @default.
• W3124328448 cites W2749460173 @default.
• W3124328448 cites W2754721894 @default.
• W3124328448 cites W2798160602 @default.
• W3124328448 cites W2802607685 @default.
• W3124328448 cites W2887435797 @default.
• W3124328448 cites W2889444510 @default.
• W3124328448 cites W2889646458 @default.
• W3124328448 cites W2895608724 @default.
• W3124328448 cites W2905289065 @default.
• W3124328448 cites W2918948206 @default.
• W3124328448 cites W2943360147 @default.
• W3124328448 cites W2972289446 @default.
• W3124328448 cites W2980537150 @default.
• W3124328448 cites W2981462047 @default.
• W3124328448 cites W2990438049 @default.
• W3124328448 cites W3003197494 @default.
• W3124328448 cites W3005124847 @default.
• W3124328448 cites W3006038212 @default.
• W3124328448 cites W3007406304 @default.
• W3124328448 cites W3010093658 @default.
• W3124328448 cites W3017217098 @default.
• W3124328448 cites W3047367404 @default.
• W3124328448 doi "https://doi.org/10.1016/j.lungcan.2021.01.018" @default.
• W3124328448 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33529989" @default.
• W3124328448 hasPublicationYear "2021" @default.
• W3124328448 type Work @default.
• W3124328448 sameAs 3124328448 @default.
• W3124328448 citedByCount "40" @default.
• W3124328448 countsByYear W31243284482021 @default.
• W3124328448 countsByYear W31243284482022 @default.
• W3124328448 countsByYear W31243284482023 @default.
• W3124328448 crossrefType "journal-article" @default.
• W3124328448 hasAuthorship W3124328448A5004352238 @default.
• W3124328448 hasAuthorship W3124328448A5010070565 @default.
• W3124328448 hasAuthorship W3124328448A5010632119 @default.
• W3124328448 hasAuthorship W3124328448A5013804417 @default.
• W3124328448 hasAuthorship W3124328448A5024703489 @default.
• W3124328448 hasAuthorship W3124328448A5025974644 @default.
• W3124328448 hasAuthorship W3124328448A5046577049 @default.
• W3124328448 hasAuthorship W3124328448A5053291675 @default.
• W3124328448 hasAuthorship W3124328448A5055278162 @default.
• W3124328448 hasAuthorship W3124328448A5058552522 @default.
• W3124328448 hasAuthorship W3124328448A5061019810 @default.
• W3124328448 hasAuthorship W3124328448A5064807273 @default.
• W3124328448 hasAuthorship W3124328448A5072714653 @default.
• W3124328448 hasAuthorship W3124328448A5076234765 @default.
• W3124328448 hasAuthorship W3124328448A5078217749 @default.
• W3124328448 hasAuthorship W3124328448A5085505239 @default.
• W3124328448 hasConcept C121608353 @default.
• W3124328448 hasConcept C126322002 @default.
• W3124328448 hasConcept C126838900 @default.
• W3124328448 hasConcept C141071460 @default.
• W3124328448 hasConcept C143998085 @default.
• W3124328448 hasConcept C146357865 @default.
• W3124328448 hasConcept C151730666 @default.
• W3124328448 hasConcept C2776256026 @default.
• W3124328448 hasConcept C2777546739 @default.
• W3124328448 hasConcept C2777701055 @default.
• W3124328448 hasConcept C2778292576 @default.
• W3124328448 hasConcept C2780057760 @default.

• next